DE60335639D1 - Prävention und/oder behandlung von colitis ulcerosa mit pyy oder pyyä3-36ü - Google Patents
Prävention und/oder behandlung von colitis ulcerosa mit pyy oder pyyä3-36üInfo
- Publication number
- DE60335639D1 DE60335639D1 DE60335639T DE60335639T DE60335639D1 DE 60335639 D1 DE60335639 D1 DE 60335639D1 DE 60335639 T DE60335639 T DE 60335639T DE 60335639 T DE60335639 T DE 60335639T DE 60335639 D1 DE60335639 D1 DE 60335639D1
- Authority
- DE
- Germany
- Prior art keywords
- pyy
- bowel
- pyye3
- prevention
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2066—IL-10
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2073—IL-11
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Endocrinology (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38893002P | 2002-06-14 | 2002-06-14 | |
PCT/US2003/018657 WO2003105763A2 (en) | 2002-06-14 | 2003-06-13 | Prevention and/or treatment of inflammatory bowel disease using pyy or agonists thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60335639D1 true DE60335639D1 (de) | 2011-02-17 |
Family
ID=29736565
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60335639T Expired - Lifetime DE60335639D1 (de) | 2002-06-14 | 2003-06-13 | Prävention und/oder behandlung von colitis ulcerosa mit pyy oder pyyä3-36ü |
Country Status (6)
Country | Link |
---|---|
US (1) | US20060122106A1 (de) |
EP (1) | EP1549336B1 (de) |
AT (1) | ATE494002T1 (de) |
AU (1) | AU2003243545A1 (de) |
DE (1) | DE60335639D1 (de) |
WO (1) | WO2003105763A2 (de) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA03005388A (es) | 2000-12-14 | 2003-09-25 | Amylin Pharmaceuticals Inc | Peptido yy y agonistas de peptido yy para el tratamiento de desordenes metabolicos. |
US7186692B2 (en) | 2002-12-17 | 2007-03-06 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity |
BR0316685A (pt) | 2002-12-17 | 2005-11-01 | Nastech Pharm Co | Composições e métodos para a administração aperfeiçoada por via mucosal de peptìdeos fixadores ao receptor de y2 e métodos para tratar e prevenir a obesidade |
EP1599468B1 (de) | 2003-01-14 | 2007-10-03 | Arena Pharmaceuticals, Inc. | 1,2,3-trisubstituierte aryl- und heteroarylderivate als modulatoren des metabolismus zur vorbeugung und behandlung von metabolismus-bedingten krankheiten wie diabetes oder hyperglykämie |
EP2335715A3 (de) | 2004-02-11 | 2013-12-18 | Amylin Pharmaceuticals, LLC | Pankreas-polypeptidfamilienmotive und diese enthaltende polypeptide |
WO2005077072A2 (en) | 2004-02-11 | 2005-08-25 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides with selectable properties |
AU2005224026A1 (en) | 2004-03-17 | 2005-09-29 | 7Tm Pharma A/S | Y2 selective receptor agonists for therapeutic interventions |
WO2005089790A2 (en) | 2004-03-17 | 2005-09-29 | 7Tm Pharma A/S | Y2/y4 selective receptor agonists for therapeutic interventions |
KR101272402B1 (ko) | 2004-12-13 | 2013-06-10 | 아스트라제네카 파마수티컬스 엘피 | 췌장 폴리펩티드 족 모티프, 폴리펩티드 및 이를 포함하는방법 |
KR20070115947A (ko) | 2005-02-11 | 2007-12-06 | 아밀린 파마슈티칼스, 인크. | 선택가능한 특성들을 가지는 gip 유사체 및 하이브리드폴리펩타이드 |
CN101193626A (zh) * | 2005-03-11 | 2008-06-04 | 益德威士医药股份有限公司 | 奥曲肽的受控释放制剂 |
US7759312B2 (en) * | 2005-03-11 | 2010-07-20 | Endo Pharmaceuticals Solutions Inc. | Delivery of dry formulations of octreotide |
EP2330125A3 (de) | 2005-08-11 | 2012-12-12 | Amylin Pharmaceuticals, Inc. | Hybridpolypeptide mit auswählbaren Eigenschaften |
AU2006279680B2 (en) | 2005-08-11 | 2012-12-06 | Amylin Pharmaceuticals, Llc | Hybrid polypeptides with selectable properties |
EP2146210A1 (de) | 2008-04-07 | 2010-01-20 | Arena Pharmaceuticals, Inc. | Verfahren zur Verwendung eines AG-Protein-gekoppelten Rezeptors zur Identifikation von Peptid-YY (PPY)-Sekretagogen sowie Verbindungen zur Behandlung durch PYY modulierter Leiden |
WO2009158415A1 (en) * | 2008-06-25 | 2009-12-30 | Endo Pharmaceuticals Solutions Inc. | Octreotide implant having a release agent |
EP2303226B1 (de) * | 2008-06-25 | 2016-03-23 | Endo Pharmaceuticals Solutions Inc. | Verlängerte freisetzung von exenatid und anderen polypeptiden |
GB0817067D0 (en) * | 2008-09-18 | 2008-10-22 | 7Tm Pharma As | Intestinal treatment |
AR077642A1 (es) | 2009-07-09 | 2011-09-14 | Arena Pharm Inc | Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo |
JP2013505221A (ja) | 2009-09-18 | 2013-02-14 | ノヴォ ノルディスク アー/エス | 長時間作用性y2受容体アゴニスト |
JP2013510829A (ja) | 2009-11-13 | 2013-03-28 | ノヴォ ノルディスク アー/エス | 長時間作用型y2受容体アゴニスト |
EP2556056A1 (de) | 2010-04-06 | 2013-02-13 | Arena Pharmaceuticals, Inc. | Modulatoren des gpr119-rezeptors und behandlung von damit assoziierten erkrankungen |
KR101871011B1 (ko) | 2010-09-22 | 2018-06-25 | 아레나 파마슈티칼스, 인크. | Gpr119 수용체의 조절제 및 그와 관련된 장애의 치료 |
WO2012135570A1 (en) | 2011-04-01 | 2012-10-04 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012145361A1 (en) | 2011-04-19 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012145604A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012145603A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
MX2017008925A (es) | 2015-01-06 | 2017-10-11 | Arena Pharm Inc | Metodos de condiciones de tratamiento relacionadas con el receptor s1p1. |
PT3310760T (pt) | 2015-06-22 | 2022-11-10 | Arena Pharm Inc | Sal cristalino de l-arginina de ácido (r)-2-(7-(4-ciclopentil-3-(trifluorometil)benziloxi)-1,2,3,4-tetrahidrociclo-penta[b]indol-3-il)acético para utilização em distúrbios associados a recetores de s1p1 |
JP2020507611A (ja) | 2017-02-16 | 2020-03-12 | アリーナ ファーマシューティカルズ, インコーポレイテッド | 原発性胆汁性胆管炎の治療のための化合物および方法 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4891357A (en) * | 1985-02-11 | 1990-01-02 | University Of Florida | Methods and compositions for stimulation of appetite |
US4683195A (en) * | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4683202A (en) * | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4839343A (en) * | 1987-03-13 | 1989-06-13 | Debiopharm, S.A. | Preparation containing hexatriacontapeptides and methods of use |
US4892538A (en) * | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
WO1990006952A1 (en) * | 1988-12-22 | 1990-06-28 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
US5459039A (en) * | 1989-05-12 | 1995-10-17 | Duke University | Methods for mapping genetic mutations |
US5214066A (en) * | 1990-04-18 | 1993-05-25 | Brigham And Women's Hospital | Method for producing an animal model for inflammatory bowel disease including ulcerative colitis |
US6391343B1 (en) * | 1991-01-15 | 2002-05-21 | Hemosphere, Inc. | Fibrinogen-coated particles for therapeutic use |
AU685803B2 (en) * | 1993-03-29 | 1998-01-29 | University Of Cincinnati, The | Analogs of peptide YY and uses thereof |
US5498531A (en) * | 1993-09-10 | 1996-03-12 | President And Fellows Of Harvard College | Intron-mediated recombinant techniques and reagents |
US5545549A (en) * | 1994-02-03 | 1996-08-13 | Synaptic Pharmaceutical Corporation | DNA encoding a human neuropeptide Y/peptide YY (Y2) receptor and uses thereof |
US5824784A (en) * | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
US5696093A (en) * | 1994-10-28 | 1997-12-09 | Crc For Biopharmaceutical Research Pty Limited | Method of treating nasal congestion using neuropeptide Y Y2 agonist peptides |
US5574010A (en) * | 1994-11-14 | 1996-11-12 | The Regents Of The University Of California | Treatment of pancreatic tumors with peptide YY and analogs thereof |
US5602024A (en) * | 1994-12-02 | 1997-02-11 | Synaptic Pharmaceutical Corporation | DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof |
US5912227A (en) * | 1995-01-27 | 1999-06-15 | North Carolina State University | Method of enhancing nutrient uptake |
US20020094346A1 (en) * | 1995-05-17 | 2002-07-18 | M. D. Henry C. Lin | Method and compositions for improving digestion and absorption in the small intestine |
US6558708B1 (en) * | 1995-05-17 | 2003-05-06 | Cedars-Sinai Medical Center | Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia |
US5980945A (en) * | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
US6355478B1 (en) * | 1996-06-17 | 2002-03-12 | Eli Lilly And Company | Rhesus monkey neuropeptide Y Y2 receptor |
AU6144098A (en) * | 1997-02-14 | 1998-09-08 | Bayer Corporation | Amide derivatives as selective neuropeptide y receptor antagonists |
JP3036480B2 (ja) * | 1997-08-25 | 2000-04-24 | 日本電気株式会社 | バーコード読取装置およびその焦点制御方法 |
US6013622A (en) * | 1998-04-15 | 2000-01-11 | Nutriceutical Technology Corporation | Method of regulating appetite and metabolism |
US6046179A (en) * | 1998-04-17 | 2000-04-04 | Murch; Simon | Composition for and treatment of inflammatory bowel disease by colon administration of N-acetylglucosamine |
DE69911975T2 (de) * | 1998-07-31 | 2004-09-09 | Novo Nordisk A/S | In-vitro stimulation von beta zellen vermehrung |
IE990033A1 (en) * | 1999-01-15 | 2000-10-18 | Entpr Ie Trd As Bioresearch Ie | Bifidobacterium longum infantis in the treatment of inflammatory bowel disease |
US7745216B2 (en) * | 1999-02-10 | 2010-06-29 | Curis, Inc. | Methods and reagents for treating glucose metabolic disorders |
US6569832B1 (en) * | 1999-11-12 | 2003-05-27 | Novo Nordisk A/S | Inhibition of beta cell degeneration |
US6734166B1 (en) * | 2000-02-08 | 2004-05-11 | North Carolina State University | Method of reducing aluminum levels in the central nervous system |
-
2003
- 2003-06-13 AT AT03760322T patent/ATE494002T1/de not_active IP Right Cessation
- 2003-06-13 DE DE60335639T patent/DE60335639D1/de not_active Expired - Lifetime
- 2003-06-13 AU AU2003243545A patent/AU2003243545A1/en not_active Abandoned
- 2003-06-13 WO PCT/US2003/018657 patent/WO2003105763A2/en not_active Application Discontinuation
- 2003-06-13 US US10/518,128 patent/US20060122106A1/en not_active Abandoned
- 2003-06-13 EP EP03760322A patent/EP1549336B1/de not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
ATE494002T1 (de) | 2011-01-15 |
AU2003243545A8 (en) | 2003-12-31 |
EP1549336A4 (de) | 2008-01-02 |
WO2003105763B1 (en) | 2004-09-02 |
AU2003243545A1 (en) | 2003-12-31 |
WO2003105763A3 (en) | 2004-06-17 |
EP1549336A2 (de) | 2005-07-06 |
WO2003105763A2 (en) | 2003-12-24 |
EP1549336B1 (de) | 2011-01-05 |
US20060122106A1 (en) | 2006-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE494002T1 (de) | Prävention und/oder behandlung von colitis ulcerosa mit pyy oder pyyä3-36ü | |
ES2196303T3 (es) | Administracion de nicotina por el colon para tratar enfermedades intestinales inflamatorias. | |
GB0318447D0 (en) | Therapeutic agents | |
GB0225475D0 (en) | Therapeutic agents | |
GB0223038D0 (en) | Therapeutic compounds | |
EA200300717A1 (ru) | Гетероциклилиндазольные и -азаиндазольные соединения в качестве 5-гидрокситриптамин-6-лигандов | |
ATE401076T1 (de) | Chinolinderivate als glucokinase liganden | |
NO20044475L (no) | 2-(2,6-diklorfenyl)-diarulimidazoler | |
WO2005072113A3 (en) | Compositions and methods of treatment for inflammatory diseases | |
NO20015607D0 (no) | Glukagonantagonister/inversagonister | |
NO20023962D0 (no) | Bruk av IL-18-inhibitorer | |
EA200300716A1 (ru) | Гетероциклилалкилиндольные или -азаиндольные соединения в качестве лиганд 5-гидрокситриптамина-6 | |
ES2184097T3 (es) | Nuevos compuestos. | |
MXPA04000891A (es) | Nuevos derivados de acido vinilcarboxilico y su uso como antidiabeticos. | |
PT1017404E (pt) | Formulacao farmaceutica para o tratamento de doenca inflamatoria do intestino | |
SE0203825D0 (sv) | Novel fused heterocycles and uses thereof | |
EP1284265A4 (de) | Benzothiophenderivate und deren medizinische verwendungen | |
CY1111900T1 (el) | Θεραπεια του νευροπαθητικου πονου με ανταγωνιστες υποδοχεα ν-μεθυλ-d-ασπαρτικων (nmda) | |
PL376704A1 (pl) | Nowe związki przydatne w leczeniu chorób, w których pośredniczy PPAR | |
DE69726174D1 (de) | Verhütung von magen-darm schäden | |
ES2092645T3 (es) | Metanoantracenos como antagonistas de dopamina. | |
ATE357931T1 (de) | Mittel zur prävention/behandlung entzündlicher darmerkrankungen | |
CO4790098A1 (es) | Composicion para el tratamiento de trastornos gastrointes- tinales y metodo para su fabricacion | |
GB2010812A (en) | Medicaments acting notably on the central nervous system based on ethyl 2-aryl allophanates | |
DE60126504D1 (de) | Verwendung von gegen candida wirksamen mitteln zur behandlung von störungen der oralen und intestinalen mucosa |